Table 2.

Randomized controlled trials (RCTs) for treating various conditions with UA-ADCRs reported in the literature (c.f. [67]).

Study	Usuelli et al. (2018) [75]	Koh et al. (2014) [76]	Koh et al. (2016) [77]	Han et al. (2010) [78]	Raposio et al. (2016) [79]	Malik et al. (2019) [80]
Indication	Achilles tendinopathy	Knee OA	Knee OA	Skin ulcers	Skin ulcers	Painful amputation stump
N (Tr)	21	26	30	28	16	5
Tr	UA-ADRCs	HTO + UA-ADRCs + PRP	MF + UA-ADRCs	UA-ADRCs + Fibrin	UA-ADRCs + PRP	UA-ADRCs + Fat
I-PoC	Yes	No (1 day before)	No (1 day before)	Yes	Yes	Yes
N (C)	23	26	27	26	24	5
C	PRP	HTO + PRP	MF	Fibrin	PRP	Fat
E/NE	NE	E	E	E	E	E
Follow-up	M6	M24	M26-M30	W8	M18	M6
Tr > C	No	Yes	Yes*	Yes	No**	No

Abbreviations: OA, osteoarthritis; N (Tr), number of subjects in the treatment group; Tr, treatment; HTO, high tibial osteotomy, UA-ADRCs, uncultured, autologous, adipose derived regenerative cells; HTO, open-wedge high tibial osteotomy; PRP, platelet rich plasma; MF, microfractures; I-PoC, isolation of ADRCs at the point of care; N (C), number of subjects in the control group; C, control treatment; E/NE, enzymatic/non-enzymatic isolation of ADRCs; M, month; W, week; Tr > C, outcome after treatment superior to outcome after control treatment. *, only short-term effects (c.f. main text); ** when all subjects were considered that were enrolled in this study.